Welcome to our dedicated page for Rapt Therapeutics news (Ticker: RAPT), a resource for investors and traders seeking the latest updates and insights on Rapt Therapeutics stock.
RAPT Therapeutics, Inc. (RAPT) is a clinical-stage biopharmaceutical leader developing oral therapies for oncology and inflammatory diseases. This news hub provides investors and industry professionals with verified updates on the company's scientific advancements and corporate developments.
Comprehensive Resource: Track all official announcements including clinical trial milestones, regulatory submissions, financial results, and strategic partnerships. Our curated collection ensures efficient access to material developments affecting RAPT's position in immunology-focused drug discovery.
Key Coverage Areas: Stay informed about CCR4-targeting therapies like tivumecirnon (FLX475) and inflammatory disease candidates such as zelnecirnon (RPT193). Receive updates on FDA communications, research collaborations, and pipeline expansion efforts without speculative commentary.
Strategic Monitoring: Bookmark this page for real-time access to primary source materials. Professionals relying on precision medicine updates will find this centralized repository essential for tracking RAPT's progress in addressing unmet medical needs through innovative immunology approaches.
RAPT Therapeutics has successfully closed its underwritten public offering of 4,356,060 shares of common stock at $33.00 per share, raising approximately $143.7 million before expenses. This includes 568,181 shares sold due to underwriters' full exercise of their option. The offering was made under an effective shelf registration statement filed with the SEC. J.P. Morgan, SVB Leerink, and Piper Sandler acted as joint lead book-running managers for this offering.
RAPT Therapeutics, a clinical-stage biopharmaceutical company, has announced a public offering of 3,787,879 shares at $33.00 each, aiming for approximately $125 million in gross proceeds. The offering, set to close on June 18, 2021, is managed by J.P. Morgan, SVB Leerink, and Piper Sandler. A 30-day option for underwriters to purchase an additional 568,181 shares is also available. This offering follows a shelf registration with the SEC that was effective on November 16, 2020.
RAPT Therapeutics, Inc. (Nasdaq: RAPT) has announced a public offering of $125 million in common stock, with an option for underwriters to purchase an additional $18.75 million. The offering is contingent on market conditions and is governed by a previously filed shelf registration statement with the SEC. J.P. Morgan, SVB Leerink, and Piper Sandler are the lead managers for the offering. This fundraising aims to support RAPT's development of oral therapies targeting significant unmet needs in oncology and inflammatory diseases.
RAPT Therapeutics announced positive topline results from its Phase 1b trial of RPT193 for moderate-to-severe atopic dermatitis. After four weeks, patients showed a 36.3% improvement in the Eczema Area and Severity Index (EASI) compared to 17.0% in the placebo group. Notably, a 53.2% improvement was recorded six weeks post-treatment. RPT193 was well tolerated with no serious adverse events. RAPT plans to advance RPT193 into a Phase 2b trial in atopic dermatitis and a Phase 2a trial in asthma.
RAPT Therapeutics (Nasdaq: RAPT) announced it will release top-line results from its Phase 1b clinical trial of RPT193 for moderate to severe atopic dermatitis on June 14, 2021. This key data announcement signifies the company's ongoing commitment to addressing unmet medical needs in inflammatory diseases. The results will be shared during a conference call at 8:30 a.m. ET, which will be accessible via a live webcast. RAPT is developing targeted oral therapies focusing on CCR4, with RPT193 as a notable candidate in its pipeline.
RAPT Therapeutics, a clinical-stage biopharmaceutical company, announced that its CEO Brian Wong will participate in a fireside chat at the UBS Global Healthcare Virtual Conference on May 24, 2021, at 3:00 pm Eastern Time. The event aims to discuss the company’s advancements in developing oral small molecule therapies for oncology and inflammatory diseases. Interested parties can access the live webcast and archived recording on the RAPT Therapeutics website. The company is focused on developing selective small molecules targeting critical immune drivers, including drug candidates FLX475 and RPT193.
RAPT Therapeutics reported a net loss of $16.5 million for Q1 2021, up from $13.1 million in Q1 2020. Research and development expenses rose to $13.8 million due to increased clinical trial costs and personnel expenses. General and administrative expenses increased to $4.0 million, impacted by higher stock-based compensation and insurance costs. The company is progressing in its oncology and inflammation programs, highlighting recent preclinical data and the completion of enrollment in a Phase 1b trial for RPT193. Cash and equivalents stood at $98.4 million as of March 31, 2021.
RAPT Therapeutics has completed enrollment in its Phase 1b clinical trial of RPT193 for moderate to severe atopic dermatitis, with results expected by mid-2021. The trial aims to establish safety and clinical efficacy through multiple endpoints, including the Eczema Area and Severity Index and pruritis scale. An encouraging outcome may position RPT193 as a viable oral treatment option against existing injectable therapies, targeting significant unmet needs in inflammatory diseases.
RAPT Therapeutics (Nasdaq: RAPT) announced its financial results for Q4 and the year ending December 31, 2020. The company reported a net loss of $12.7 million for Q4 2020, slightly better than the $13.2 million loss in Q4 2019. Annual net loss increased to $52.9 million from $43 million in 2019. Research and development expenses rose to $45.5 million in 2020, driven by clinical trial costs for FLX475 and RPT193. As of December 31, 2020, cash and equivalents totaled $111.5 million. Key clinical advancements were noted for both lead programs, with upcoming data readouts expected in 2021.
RAPT Therapeutics (RAPT) reported promising data from preclinical studies to be presented at the American Association for Cancer Research annual meeting. Key findings include the ability of CCR4 antagonists to enhance CAR T-cell therapy's efficacy in solid tumors, with a significant increase in survival rates in murine models. Additionally, small-molecule HPK1 inhibitors demonstrated enhanced T-cell responses, while GCN2 inhibitors showed potential to restore immunity in the tumor microenvironment. These developments highlight RAPT's ongoing commitment to advancing immunology-based therapies for cancer treatment.
